Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

【Breaking News!】 First MASH treatment approved by FDA

On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res…

READ MORE

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…

READ MORE

New

Sci Rep.,

“Periodontitis promotes hepatocellular carcinoma in Stelic Animal model (STAM) mice” (Sci. Rep., DOI: 10.1038/s41598-024-68422-7, 2024)

READ MORE

STAM™ model

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

COLUMN

2025.02.21

Get the Latest BDL Model Material

We are pleased to share with you the latest material introducing our BDL model, which should provide valuable …

READ MORE

2025.02.14

Get Latest UUO Model Material

We are pleased to share the latest material introducing our UUO model, which should provide valuable insights …

READ MORE

2025.02.07

Pulse oximetry analysis of IPF model mice

Pulse oximetry analysis begins in IPF preclinical pharmacology study.   We offer the Idiopathic Pulmonary…

READ MORE

2025.02.06

[CAIA research seen in an example study] Custom model service for realizing a wide range of research

In recent years, we have received many requests about our services, starting from the establishment of patholo…

READ MORE

2025.02.05

[Case Study] Why do disease model mice change the outcomes?

If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of …

READ MORE

2025.02.04

Infliximab (TNF-a antibody) data in IBD model

We introduce some of the data, the results for Infliximab (TNF-a antibody), from the full version of the IBD m…

READ MORE

VIEW MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ model

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

Bile duct ligation (BDL) model

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2024.12.27

Case study: Study published in Periodontitis promotes hepatocellular carcinoma Stelic Animal model mice.

We introduce a case study of basic research using our MASH model (STAM™ model).   It has been reported th…

READ MORE

2024.12.09

CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC

CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. …

READ MORE

2024.11.28

Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.

We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (ST…

READ MORE

2024.11.15

PUBLICATION

Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~

Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (Nove…

READ MORE

2024.11.05

Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.

We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and af…

READ MORE

2024.10.24

Preclinical HCC study with positive control, Lenvatinib

We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improv…

READ MORE

VIEW MORE